Antiviral Therapy

Papers
(The median citation count of Antiviral Therapy is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Commentary: Development of Therapeutics for Congenital Cytomegalovirus Infection27
A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients25
HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective16
The making of the one pill—Developing single tablet regimens for HIV and for HCV15
Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting14
Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation13
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants13
Commentary: John C. Martin (1951–2021)12
Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts12
A rare complication of coronary vasospasm associated with concomitant use of ergotamine, cobicistat, and darunavir10
Changes in blood lipids in patients with chronic hepatitis B after 48 weeks of tenofovir alafenamide treatment: A prospective real-world clinical study10
Tenofovir alafenamide fumarate9
In-silico approach to characterize the structure and function of a hypothetical protein of Monkeypox virus exploring Chordopox-A20R domain-containing protein activity9
RVX-208, an inducer of Apolipoprotein A-I, inhibits the particle production of hepatitis B virus through activation of cGAS-STING pathway9
Dolutegravir and rilpivirine as successful initial antiretroviral therapy in a treatment-naive patient with HIV-1: A case report8
Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis6
A favipiravir-induced angioedema and urticaria in a COVID-19 patient6
Andrographolide suppresses SARS-CoV-2 infection by downregulating ACE2 expression: A mechanistic study6
Seroprevalence, seroconversion, and mother-to-child transmission of dual and triplex infections of HIV, HBV, and HCV among Nigerian obstetric population: A national multicentre prospective cohort stud6
The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review6
Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach6
The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir6
Durability of multi-drug antiretroviral therapy (mega-ART) in treatment-experienced people with HIV in the ARCA database5
The transformation of HIV therapy: One pill once a day5
Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical s5
Polaris Observatory—supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis4
Antiretroviral therapy adherence patterns, virological suppression, and emergence of drug resistance: A nested case–control study from Uganda and South Africa4
Sustained viral suppression with once daily dolutegravir-containing regimen in presence of the strong inducer carbamazepine4
Progress in the quality of care for newly diagnosed people with HIV in Spain (2004–2019)4
Analysis of risk factors and prediction model construction for varicella encephalitis in children: A retrospective cohort study4
Waitlist-controlled trial of an online intervention to address mental health among older people living with HIV4
Efficacy of second-line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor4
Clinical outcomes in patients with mild to moderate coronavirus disease 2019 treated with monoclonal antibody therapy versus an untreated control cohort4
Lipid and glucose abnormalities and associated factors among children living with HIV in Asia4
Antiviral potential of phenolic compounds against HSV-1: In-vitro study4
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B3
Providing access to high-quality, low-cost medicines across low and middle-income countries (LMICs), working with governments and generic manufacturers around the globe - A business case3
Feminizing hormone therapy in a Canadian cohort of transgender women with and without HIV3
Inhibition of chikungunya virus replication by N-ω-Chloroacetyl-L-Ornithine in C6/36, Vero cells and human fibroblast BJ3
Preface: Special Collection Commemorating John C. Martin3
Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives3
Understanding the effect of direct-acting antiviral therapy on weight in patients with chronic hepatitis C3
Antiviral prophylaxis for hepatitis B virus in COVID-19 patients treated with immunosuppressive drug therapy2
Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study2
Subacute thyroiditis following COVID-19 vaccination: Case presentation2
Increased insulin resistance following switch from efavirenz to cobicistat-boosted elvitegravir2
Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-192
Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report2
Resistance levels to non-nucleoside reverse transcriptase inhibitors among pregnant women with recent HIV infection in Malawi2
Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients2
Preemptive acyclovir to prevent herpes simplex virus bronchopneumonitis in mechanically ventilated patients with herpes simplex virus oropharyngeal reactivation: An ancillary study of the preemptive t2
The curing regimens of HCV: A SWOT analysis2
Herpes simplex virus reactivation in patients with COVID-19 and acute respiratory distress syndrome: a prospective cohort study2
0.02197003364563